Concise Prescribing Info
Initial treatment of advanced ovarian carcinoma of epithelial origin in established combinations w/ other approved chemotherapeutic agents. Palliative treatment of ovarian carcinoma of epithelial origin refractory to standard chemotherapy w/ or w/o cisplatin. Small cell lung carcinoma (SCLC).
Dosage/Direction for Use
Previously untreated patient w/ normal renal function 400 mg/m2 IV infusion over 15-60 min every 4 wk. Recurrent ovarian cancer Initially 360 mg/m2 IV once every 4 wk. Advanced ovarian cancer (stage III & IV) 300 mg/m2 carboplatin IV in combination w/ cyclophosphamide. Patient w/ renal impairment CrCl 41-59 mL/min Initial dose: 250 mg/m2. 16-40 mL/min Initial dose: 200 mg/m2.
Hypersensitivity to carboplatin, cisplatin or other platinum-containing compd & mannitol. Preexisting severe renal impairment (CrCl <30 mL/min); severe myelosuppression, bleeding tumors, yellow fever vaccine. Pregnancy & lactation.
Special Precautions
Perform blood counts, neurological, renal & hepatic function tests regularly. Do not administer more frequently than every 4 wk. Discontinue use if severe myelosuppression or abnormal renal or hepatic function occur. Risk of bone marrow suppression, myelosuppression, hematologic-, nephro- & neurotoxicity, ototoxicity, GI reactions, anaphylaxis, immunosuppressant effects/increased susceptibility to infections, loss of vision (high dose). Male patients should not father a child during & 6-mth post-treatment. May affect ability to drive or operate machinery. Childn. Elderly.
Adverse Reactions
Secondary acute malignancies, myeloid leukemia, myelodysplastic syndrome; infection; blood & lymphatic, immune system, metabolism & nutrition, nervous system, eye, ear & labyrinth, cardiac, vascular, resp thoracic & mediastinal. GI, skin & SC, musculoskeletal & connective tissue, renal & urinary effects; mucous membrane disorder, abnormal renal function, acute renal failure; mucous membrane disorder, asthenia, malaise, fever, mucositis, fatigue, pain, flu-like symptoms; decreased CrCl, increased BUN, blood alkaline phosphatase, aspartate aminotransferase; decreased blood Na, K, Ca, Mg; increased blood bilirubin, creatinine, uric acid; ototoxicity, inj site reaction, necrosis, extravasation, erythema.
Drug Interactions
Al, anticoagulants. Potentiated hematologic toxicity w/ myelosuppressive agents or radiation therapy. Reduced digestive absorption of phenytoin/fosphenytoin. Increased nephro- or ototoxicity risks (w/ nephro- or ototoxic agents eg aminoglycosides, vancomycin, capreomycin & diuretics); incidence of emesis w/ emetogenic agents. Live attenuated vaccines.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
Biovinate soln for infusion 150 mg/15 mL
25 mL x 1's
Biovinate soln for infusion 450 mg/45 mL
50 mL x 1's (P6,427/vial)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in